Inhibitors 1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4.

A compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar is phenyl, pyridyl, pyrimidyl, indolyl, quilnolinilo, thienyl, pyridonyl, oxazolyl, oxadiazolyl, thiadiazolyl, or imidazolyl, or oxides thereof when Ar is a heteroaryl; R is H or -alquiloC1-6; R1 is H, or a group -alquiloC1-6, -cicloalquiloC3 ~ 6 -alcoxiC1-6, -alqueniloC2-6, C3-6 -alkynyl, heteroaryl, or heterocycle, optionally substituted with 1 to 3 independent substituents -alkyl C1- 66, -alcoxiC1-6, OH, amino, (alquilCo_6) -SON- (C1-6alkyl), nitro, CN, = NO-C1-6 alkyl, -ON = C1-6alkyl, or halogen; R2 is H, halogen, -alquiloC1-6, -cicloalquiloC3-6, -alquilC1-6 (cicloalquiIC3 ~ 6) (~ 6 cicloalquiloC3), -alcoxiC1-66, phenyl, heteroaryl, heterocycle, amino, -C (O) - C1-6alkyl, -C (O) -O-alquiloC1-66, -alquilC1 ~ 6 (= NOH), -C (N = NOH) C 1-6 alkyl, -alquilC066 (oxy) alquilC1 ~ 6-phenyl, -SOnNH (alquiloC066), or - (alquilC0_66) -SON- (1-6C alkyl), wherein the phenyl, heteroaryl oheterociclo is optionally substituted with halogen, -alquiloC1-66, -alcoxiC1-6, hydroxy, amino, or -C ( O) -O-C1-6alkyl, and any alkyl is optionally substituted 1-6 independent halogen or -OH; n is 0, 1, or 2; R3 is H, OH, amine, halogen or C1 ~ 6, wherein the alkyl is optionally substituted 1-6 ssustituyente independent halogen, OH, or amine; and R4, R5, R6, and R7 each independently is H, halogen, -alquiloC1-6, -alcoxiC1-6, or amine, and any alkyl is optionally substituted with 1-6 independent halogen or -OH.